Effects of ZofranSeveral studies have looked at how well Zofran prevents nausea and vomiting due to several causes.
One study looked at Zofran for chemotherapy regimens that were likely to cause nausea and vomiting. Of the people that took the drug, 66 percent had no vomiting and 56 percent had no nausea within the first day after chemotherapy. Vomiting was much more likely for people who did not take Zofran; more than 90 percent of these people experienced vomiting. This study did not look at nausea or vomiting beyond the first day after chemotherapy.
Zofran was also studied for chemotherapy regimens that had a medium risk for nausea and vomiting. This study looked at the likelihood of vomiting during the three days after chemotherapy. For the people who took Zofran, 61 percent had no vomiting, compared to only 6 percent with no vomiting for those who did not take it. Another study showed that the drug continued to be effective for additional cycles of chemotherapy.
Chemotherapy and Children
Several studies have looked at using Zofran to prevent vomiting in children (ages 4 to 18) receiving chemotherapy. These studies showed that the medication was just as effective in children as it was in adults.
Several studies have looked at how well Zofran prevents nausea and vomiting for people undergoing radiation treatments. In studies of people having total body irradiation and daily fractionated radiation, people who took this drug were less likely to have vomiting than people who did not take it. In a study of people having single high-dose fraction radiation, Zofran worked better than another medication, metoclopramide (Reglan®), at preventing vomiting.